Comparison of Hydrazone Heterobifunctional Cross-Linking Agents for Reversible Conjugation of Thiol-Containing Chemistry

被引:31
作者
Christie, R. James [1 ]
Anderson, Diana J. [1 ]
Grainger, David W. [1 ]
机构
[1] Colorado State Univ, Dept Chem, Ft Collins, CO 80523 USA
关键词
IN-VITRO; HPMA COPOLYMERS; PEPTIDE LINKERS; DRUG-DELIVERY; DOXORUBICIN; DESIGN; STABILITY; RELEASE; LINKAGE; TRIS(2-CARBOXYETHYL)PHOSPHINE;
D O I
10.1021/bc100049c
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
Reversible covalent conjugation chemistries that allow site- and condition-specific coupling and uncoupling reactions are attractive components in nanotechnologies, bioconjugation methods, imaging, and drug delivery systems. Here, we compare three heterobifunctional cross-linkers, containing both thiol- and amine-reactive chemistries, to form pH-labile hydrazones with hydrazide derivatives of the known and often published water-soluble polymer, poly[N-(2-hydroxypropyl methacrylamide)] (pHPMA), while subsequently coupling thiol-containing molecules to the cross-linker via maleimide addition. Two novel cross-linkers were prepared from the popular heterobifunctional cross-linking agent, succinimidyl-4-(N-maleimidomethyl) cyclohexane-l-carboxylate (SMCC), modified to contain either terminal aldehyde groups (i.e., 1-(N-3-propanal)-4-(N-maleimidomethyl) cyclohexane carboxamide, PMCA) or methylketone groups (i.e., 1-(N-3-butanone)-4-(N-maleimidomethyl) cyclohexane carboxamide, BMCA). A third cross-linking agent was the commercially available N-4-acetylphenyl maleimide (APM). PMCA and BMCA exhibited excellent reactivity toward hydrazide-derivatized pHPMA with essentially complete hydrazone conjugation to polymer reactive sites, while APM coupled only similar to 60% of available reactive sites on the polymer despite a 3-fold molar excess relative to polymer hydrazide groups. All polymer hydrazone conjugates bearing these bifunctional agents were then further reacted with thiol-modified tetramethylrhodamine dye, confirming crosslinker maleimide reactivity after initial hydrazone polymer conjugation. Incubation of dye-labeled polymer conjugates in phosphate buffered saline at 37 degrees C showed that hydrazone coupling resulting from APM exhibited the greatest difference in stability between pH 7.4 and 5.0, with hydrolysis and dye release increased at pH 5.0 over a 24 h incubation period. Polymer conjugates bearing hydrazones formed from cross-linker BMCA exhibited intermediate stability with hydrolysis much greater at pH 5.0 at early time points, but hydrolysis at pH 7.4 was significant after 5 h. Hydrazones formed with the PMCA cross-linker showed no difference in release rates at pH 7.4 and 5.0.
引用
收藏
页码:1779 / 1787
页数:9
相关论文
共 43 条
[1]   Exploitation of intracellular pH gradients in the cellular delivery of macromolecules [J].
Asokan, A ;
Cho, MJ .
JOURNAL OF PHARMACEUTICAL SCIENCES, 2002, 91 (04) :903-913
[2]   Design of environment-sensitive supramolecular assemblies for intracellular drug delivery: Polymeric micelles that are responsive to intracellular pH change [J].
Bae, Y ;
Fukushima, S ;
Harada, A ;
Kataoka, K .
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION, 2003, 42 (38) :4640-4643
[3]   A BRIEF SURVEY OF METHODS FOR PREPARING PROTEIN CONJUGATES WITH DYES, HAPTENS, AND CROSS-LINKING REAGENTS [J].
BRINKLEY, M .
BIOCONJUGATE CHEMISTRY, 1992, 3 (01) :2-13
[4]   Optical Properties and Application of a Reactive and Bioreducible Thiol-Containing Tetramethylrhodamine Dimer [J].
Christie, R. James ;
Tadiello, Constantino J. ;
Chamberlain, Lisa M. ;
Grainger, David W. .
BIOCONJUGATE CHEMISTRY, 2009, 20 (03) :476-480
[5]   MECHANISM OF HYDROLYSIS OF SCHIFF BASES DERIVED FROM ALIPHATIC AMINES [J].
CORDES, EH ;
JENCKS, WP .
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 1963, 85 (18) :2843-&
[6]   Release from polymeric prodrugs: Linkages and their degradation [J].
D'Souza, AJM ;
Topp, EM .
JOURNAL OF PHARMACEUTICAL SCIENCES, 2004, 93 (08) :1962-1979
[7]   Polyester dendritic systems for drug delivery applications:: In vitro and in vivo evaluation [J].
De Jesús, OLP ;
Ihre, HR ;
Gagne, L ;
Fréchet, JMJ ;
Szoka, FC .
BIOCONJUGATE CHEMISTRY, 2002, 13 (03) :453-461
[8]   Development of potent monoclonal antibody auristatin conjugates for cancer therapy [J].
Doronina, SO ;
Toki, BE ;
Torgov, MY ;
Mendelsohn, BA ;
Cerveny, CG ;
Chace, DF ;
DeBlanc, RL ;
Gearing, RP ;
Bovee, TD ;
Siegall, CB ;
Francisco, JA ;
Wahl, AF ;
Meyer, DL ;
Senter, PD .
NATURE BIOTECHNOLOGY, 2003, 21 (07) :778-784
[9]   Novel Peptide Linkers for Highly Potent Antibody-Auristatin Conjugate [J].
Doronina, Svetlana O. ;
Bovee, Tim D. ;
Meyer, David W. ;
Miyamoto, Jamie B. ;
Anderson, Martha E. ;
Morris-Tilden, Carol A. ;
Senter, Peter D. .
BIOCONJUGATE CHEMISTRY, 2008, 19 (10) :1960-1963
[10]  
DROBNIK J, 1976, MAKROMOL CHEM, V177, P2833